M. A. Bogomazova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
M. A. Bogomazova has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Sergey Burd
Federal Center for Brain and Neurotechnologies of the Federal Medical Biological Agency of Russia
6 shared publications - Yulia V. Rubleva
Federal Center of Brain Research and Neurotechnologies
6 shared publications - A. V. Yurchenko
Federal Center of Brain Research and Neurotechnologies
5 shared publications - N. V. Pantina
Federal Center of Brain Research and Neurotechnologies
5 shared publications - Anna V. Lebedeva
Federal Center for Brain and Neurotechnologies of the Federal Medical Biological Agency of Russia
4 shared publications - I. I. Kovaleva
Federal Center for Brain and Neurotechnologies
4 shared publications
Latest Publications
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (12) , 14-19
Ototoxicity caused by anti-epileptic drugs
According to the literature, a number of anti-epileptic drugs (AEDs) have an ototoxic effect. The mechanism of hearing dysfunction due to the use of AEDs is not well known. The main clinical manifestations of the cochleotoxic effect of the drugs are: tinnitus, sensorineural hearing loss, impaired pitch perception, hyperacusis. These disorders can be reversible and irreversible. Attending physicians should be careful when prescribing AEDs to patients who have had hearing impairment before, as well as diagnose hearing loss in a timely manner with subsequent correction of anti-epileptic therapy.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (12) , 14-19
Ototoxicity caused by anti-epileptic drugs
According to the literature, a number of anti-epileptic drugs (AEDs) have an ototoxic effect. The mechanism of hearing dysfunction due to the use of AEDs is not well known. The main clinical manifestations of the cochleotoxic effect of the drugs are: tinnitus, sensorineural hearing loss, impaired pitch perception, hyperacusis. These disorders can be reversible and irreversible. Attending physicians should be careful when prescribing AEDs to patients who have had hearing impairment before, as well as diagnose hearing loss in a timely manner with subsequent correction of anti-epileptic therapy.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (11) , 158-164
The results of a multicenter open observational study of the efficacy and safety of the dietary supplement Neururidine N in patients with acute nonspecific lower back pain in daily outpatient practice (the NEURO-N study)
Objective. To study the efficacy and safety of the use of high (200 mg) doses of uridine monophosphate in combination with choline (dietary supplement, dietary supplement, Neururidine N) in the treatment of patients with nonspecific back pain. Material and methods. An open observational study was conducted, which included 101 patients with acute PB; group 1 included 65 patients who received Neurouridine N (1 caps/day) meloxicam (7.5—15 mg/day) and meloxicam (7.5—15 mg/day), 2nd — 36 patients who received only meloxicam (7.5—15 mg/day). The observation period is 30 days. The condition of the patients was assessed on the basis of a visual analog scale (VAS), Roland—Morris questionnaires (ORM) and general clinical impression (CGI). Results. The positive effect of treatment on reducing the severity of pain was noted according to the results of the VAS assessment. In patients of group 1, an earlier improvement in functional status was noted (starting from day 7) according to ORM data (p<0.01), A more pronounced decrease in pain intensity allowed patients of group 1 to stop taking NSAIDs after 14 days (p<0.01). Patients of the 1st group were statistically significantly more satisfied with the results of treatment (CGI questionnaire), the doctors who observed them also regarded the improvement in their condition as more significant compared to the 2nd group. Conclusion. The use of dietary supplement Neururidine N is an effective and safe method of coanalgesic therapy in patients with acute LBP.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (11) , 158-164
The results of a multicenter open observational study of the efficacy and safety of the dietary supplement Neururidine N in patients with acute nonspecific lower back pain in daily outpatient practice (the NEURO-N study)
Objective. To study the efficacy and safety of the use of high (200 mg) doses of uridine monophosphate in combination with choline (dietary supplement, dietary supplement, Neururidine N) in the treatment of patients with nonspecific back pain. Material and methods. An open observational study was conducted, which included 101 patients with acute PB; group 1 included 65 patients who received Neurouridine N (1 caps/day) meloxicam (7.5—15 mg/day) and meloxicam (7.5—15 mg/day), 2nd — 36 patients who received only meloxicam (7.5—15 mg/day). The observation period is 30 days. The condition of the patients was assessed on the basis of a visual analog scale (VAS), Roland—Morris questionnaires (ORM) and general clinical impression (CGI). Results. The positive effect of treatment on reducing the severity of pain was noted according to the results of the VAS assessment. In patients of group 1, an earlier improvement in functional status was noted (starting from day 7) according to ORM data (p<0.01), A more pronounced decrease in pain intensity allowed patients of group 1 to stop taking NSAIDs after 14 days (p<0.01). Patients of the 1st group were statistically significantly more satisfied with the results of treatment (CGI questionnaire), the doctors who observed them also regarded the improvement in their condition as more significant compared to the 2nd group. Conclusion. The use of dietary supplement Neururidine N is an effective and safe method of coanalgesic therapy in patients with acute LBP.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (7) , 89-97
Study of the practice of prescribing phenosanic acid in epilepsy accompanied by asthenic disorders
Objective. To evaluate the experience of prescribing phenosanic acid in the practice of a neurologist/epileptologist when prescribing the second, third anticonvulsant drug (AED) as part of combination therapy for patients with manifestations of fatigue due to epilepsy. Material and methods. 501 patients with focal epilepsy accompanied by asthenic disorders were included in the observational program. The observation program protocol included 5 visits, including visit 1, at which screening and inclusion in the OP took place. The observation period was 10 months. At baseline and at the end of the 10-month follow-up, the patients’ condition was assessed according to the following indicators: frequency and transformation of attacks with focal onset, severity of fatigue (self-assessment scale MFI-20); quality of life (questionnaire QoLiE-10-P); frequency of attacks with focal onset. The safety of phenosanic acid (Dibufelon) was also assessed. Results. In 10 months after the inclusion of Dibufelon as the 2nd, 3rd AED in the treatment regimen, a statistically significant (p<0.01) decrease in the frequency of seizures was observed: in general — in 88% of patients; by 50% or more — in 76% of patients; transition from the group with a large number of seizures to the group with a smaller number of seizures — 74% of patients. Also when taking phenosanic acid, a positive dynamics of seizure type was noted: a reliable decrease in the proportion of patients with seizures with secondary generalization from 70% to 56%; a decrease in the number of focal seizures with impaired consciousness from 65% to 53%. In addition, there was a 38% decrease in the severity of fatigue on the MFI-20 scale (the greatest decrease on the «Mental fatigue» scale), improvement in the quality of life — a 2.7-fold increase in the mean values of the QOLIE-10 questionnaire. Conclusion. The addition of phenosanic acid to antiepileptic therapy as a second or third AED allows for better control of seizures, leading to a decrease the frequency and severity of attacks and the severity of fatigue both, and an increase of the quality of life of patients with epilepsy.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (7) , 89-97
Study of the practice of prescribing phenosanic acid in epilepsy accompanied by asthenic disorders
Objective. To evaluate the experience of prescribing phenosanic acid in the practice of a neurologist/epileptologist when prescribing the second, third anticonvulsant drug (AED) as part of combination therapy for patients with manifestations of fatigue due to epilepsy. Material and methods. 501 patients with focal epilepsy accompanied by asthenic disorders were included in the observational program. The observation program protocol included 5 visits, including visit 1, at which screening and inclusion in the OP took place. The observation period was 10 months. At baseline and at the end of the 10-month follow-up, the patients’ condition was assessed according to the following indicators: frequency and transformation of attacks with focal onset, severity of fatigue (self-assessment scale MFI-20); quality of life (questionnaire QoLiE-10-P); frequency of attacks with focal onset. The safety of phenosanic acid (Dibufelon) was also assessed. Results. In 10 months after the inclusion of Dibufelon as the 2nd, 3rd AED in the treatment regimen, a statistically significant (p<0.01) decrease in the frequency of seizures was observed: in general — in 88% of patients; by 50% or more — in 76% of patients; transition from the group with a large number of seizures to the group with a smaller number of seizures — 74% of patients. Also when taking phenosanic acid, a positive dynamics of seizure type was noted: a reliable decrease in the proportion of patients with seizures with secondary generalization from 70% to 56%; a decrease in the number of focal seizures with impaired consciousness from 65% to 53%. In addition, there was a 38% decrease in the severity of fatigue on the MFI-20 scale (the greatest decrease on the «Mental fatigue» scale), improvement in the quality of life — a 2.7-fold increase in the mean values of the QOLIE-10 questionnaire. Conclusion. The addition of phenosanic acid to antiepileptic therapy as a second or third AED allows for better control of seizures, leading to a decrease the frequency and severity of attacks and the severity of fatigue both, and an increase of the quality of life of patients with epilepsy.
- 31 January 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (1) , 28-33
Epilepsy syndromes associated with hearing loss
Пациенты с эпилепсией, у которых наблюдается снижение слуха, представляют собой отдельную группу больных, нередко имеющих отягощенный анамнез, коморбидные состояния и высокий потенциал инвалидизации. Этиопатогенетические факторы эпилепсии и тугоухости могут являться общими для данных состояний (нейроинфекции, черепно-мозговая травма, нарушение мозгового кровообращения, перинатальная патология и др.). Кроме того, эти два синдрома могут встречаться в рамках наследственных заболеваний, поэтому их своевременное распознавание и генетическая диагностика являются важными для определения дальнейшего медико-генетического прогноза. В статье приведен обзор орфанных генетических заболеваний, ассоциированных с эпилепсией и снижением слуха: синдромы MERRF, MELAS, EAST, Айме—Грипп, синдром эпилепсии, потери слуха и умственной отсталости, ассоциированного с мутациями в гене SPATA5, синдромы DOOR и Густавсона.
- 31 January 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (1) , 28-33
Epilepsy syndromes associated with hearing loss
Пациенты с эпилепсией, у которых наблюдается снижение слуха, представляют собой отдельную группу больных, нередко имеющих отягощенный анамнез, коморбидные состояния и высокий потенциал инвалидизации. Этиопатогенетические факторы эпилепсии и тугоухости могут являться общими для данных состояний (нейроинфекции, черепно-мозговая травма, нарушение мозгового кровообращения, перинатальная патология и др.). Кроме того, эти два синдрома могут встречаться в рамках наследственных заболеваний, поэтому их своевременное распознавание и генетическая диагностика являются важными для определения дальнейшего медико-генетического прогноза. В статье приведен обзор орфанных генетических заболеваний, ассоциированных с эпилепсией и снижением слуха: синдромы MERRF, MELAS, EAST, Айме—Грипп, синдром эпилепсии, потери слуха и умственной отсталости, ассоциированного с мутациями в гене SPATA5, синдромы DOOR и Густавсона.
- Open Access
- 21 July 2021
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 13 (2) , 140-146
Breach-rhythm
Electroencephalography (EEG) is one of the main non-invasive methods for examining brain activity. Cranial defects caused by trauma or surgery can lead to artifacts on the EEG such as breach-rhythm. In this article we provide a literature-based definition, pathophysiological features of the breach-rhythm, differential diagnosis between breachrhythm and epileptiform activity, as well as our own clinical case of a patient with epilepsy and breach-rhythm.
- 21 July 2021
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 13 (2) , 140-146
Open AccessBreach-rhythm
Electroencephalography (EEG) is one of the main non-invasive methods for examining brain activity. Cranial defects caused by trauma or surgery can lead to artifacts on the EEG such as breach-rhythm. In this article we provide a literature-based definition, pathophysiological features of the breach-rhythm, differential diagnosis between breachrhythm and epileptiform activity, as well as our own clinical case of a patient with epilepsy and breach-rhythm.
- Open Access
- 24 November 2020
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 12 (3) , 169-176
New-Onset Refractory Status Epilepticus (NORSE): literature review and clinical case description
New-Onset Refractory Status Epilepticus (NORSE): literature review and clinical case description
- 24 November 2020
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 12 (3) , 169-176
Open AccessNew-Onset Refractory Status Epilepticus (NORSE): literature review and clinical case description
New-Onset Refractory Status Epilepticus (NORSE): literature review and clinical case description